pairingsPairing
Germline BRCA test → adjuvant PARP inhibitor
A blood test for inherited BRCA mutations unlocks a year of olaparib after surgery, which improves survival.
OlympiA: iDFS HR 0.58, OS HR 0.72. Requires germline testing of every TNBC and high-risk HER2-negative breast cancer patient at diagnosis.
Rationale
Synthetic lethality confined to BRCA-deficient cells.
Evidence
Phase 3 OS benefit.